Results 181 to 190 of about 74,341 (223)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 2005
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level,
GOTTARDI M +2 more
openaire +3 more sources
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level,
GOTTARDI M +2 more
openaire +3 more sources
2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources
2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire +6 more sources
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire +6 more sources